FDA Neurology Roundup: June 2026

In June 2026, the FDA saw significant developments in therapies for neurological diseases, including new approvals and updates on existing treatments. This month's snapshot highlights promising advancements in both drug and device therapies, particularly in the realms of Alzheimer's and Parkinson's disease. These changes are crucial as they potentially offer better management and treatment options for millions suffering from these debilitating conditions. The FDA's proactive approach underscores its commitment to advancing healthcare through rigorous evaluation and approval processes.